



इंडियन इम्यूनोलॉजिकल्स लिमिटेड INDIAN IMMUNOLOGICALS LIMITED

Public Notice dated 27.12.2025

Regd. Anti-rabies vaccine Abhayrab

This is in reference to the recent advisory put for travellers to India by international agencies regarding our anti-rabies vaccine Abhayrab. We wish to mention that, in January 2025 we identified Abhayrab batch # KA24014, with a packaging different to the original. The company immediately notified Indian regulators and law enforcement agencies, lodged a formal complaint, and worked closely with authorities to ensure swift action.

The Abhayrab batch # KA24014 which has been manufactured and distributed across various regions of India through IIL's authorised distribution channels and NO market complaints were reported in relation to this batch. This goes on to affirm the quality and efficacy of IIL's vaccine, when procured from its authorised channels. There is no instance of any other counterfeit batch reported in the market beyond batch # KA24014.

Abhayrab® is India's first Vero cell Rabies vaccine which has been manufactured by IIL since 2000, with more than 210 million doses supplied across India and 43 countries and continues to be the brand leader with 40% market share in India.

Our vaccines are developed, manufactured, and released strictly in accordance with the applicable provisions of the Drugs and Cosmetics Act, 1940, and the Rules made thereunder. Each batch of the vaccine undergoes rigorous internal quality control testing and is released for distribution only after independent testing and batch release certification by the Central Drugs Laboratory (CDL), as mandated by the regulatory authorities.

IIL reassures stakeholders that the company's pharmacovigilance and quality systems are robust, and that the public can continue to place confidence in vaccines supplied directly by IIL and through its authorized channels.

Indian Immunologicals Limited headquartered in Hyderabad, India is a "One Health" company and one of the largest producers of vaccines in Asia. IIL was setup by National Dairy Development Board (NDDB) in 1982. IIL has multiple GMP manufacturing sites and exports to over 60 countries. IIL has a strong R&D pipeline and has launched several animal and human vaccines in the Indian market at affordable prices. IIL specializes in the development of various types of vaccines ranging from inactivated and live viral vaccines, polysaccharide conjugate vaccines, recombinant subunit vaccines, toxoid vaccines, live bacterial vaccines

Authorized Signatory:



Sunil Tiwari
VP & Head of Quality Management
For Indian Immunologicals Limited